MX347654B - Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. - Google Patents

Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion.

Info

Publication number
MX347654B
MX347654B MX2015005873A MX2015005873A MX347654B MX 347654 B MX347654 B MX 347654B MX 2015005873 A MX2015005873 A MX 2015005873A MX 2015005873 A MX2015005873 A MX 2015005873A MX 347654 B MX347654 B MX 347654B
Authority
MX
Mexico
Prior art keywords
expression
evolution
antibody
simultaneous
protein performance
Prior art date
Application number
MX2015005873A
Other languages
English (en)
Inventor
Jay Milton Short
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of MX347654B publication Critical patent/MX347654B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Abstract

La presente invención se refiere a un método de desarrollo y expresión de un anticuerpo en un hospedero de producción de células eurcariotas; el método caracterizado porque comprende: a. seleccionar un anticuerpo molde; b .desarrollar el anticuerpo molde para permitir la producción de una serie de anticuerpos mutantes en un hospedero de producción de células eurcariotas; c. examinar los anticuerpos mutantes para al menos una propiedad, característica o actividad predeterminada; d. seleccionar un anticuerpo sobre-mutante de la serie de anticuerpos mutantes con base en la optimización de la al menos una propiedad, característica o actividad predeterminada en comparación con la misma propiedad, característica o actividad predeterminada del anticuerpo molde; y e. expresar el anticuerpo sobre-mutante en el mismo hospedero de producción de células eucariotas con el paso (b) para cualquier escala comercial.
MX2015005873A 2009-07-17 2010-07-16 Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. MX347654B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27116809P 2009-07-17 2009-07-17
PCT/US2010/042302 WO2011009058A2 (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Publications (1)

Publication Number Publication Date
MX347654B true MX347654B (es) 2017-05-05

Family

ID=43450243

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005873A MX347654B (es) 2009-07-17 2010-07-16 Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion.
MX2012000803A MX2012000803A (es) 2009-07-17 2010-07-16 Selección y desarrollo integrados simultáneos del desempeño y la expresión de proteínas/anticuerpos en hospederos de producción.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012000803A MX2012000803A (es) 2009-07-17 2010-07-16 Selección y desarrollo integrados simultáneos del desempeño y la expresión de proteínas/anticuerpos en hospederos de producción.

Country Status (19)

Country Link
US (5) US8859467B2 (es)
EP (6) EP2454376B1 (es)
JP (3) JP6193570B2 (es)
KR (5) KR101823872B1 (es)
CN (2) CN102625848A (es)
AU (5) AU2010273974B2 (es)
BR (2) BR112012001171B1 (es)
CA (2) CA2768247C (es)
DK (5) DK3406717T3 (es)
ES (3) ES2652340T3 (es)
HK (1) HK1210623A1 (es)
HU (1) HUE029328T2 (es)
IN (1) IN2012DN00737A (es)
MX (2) MX347654B (es)
MY (2) MY160472A (es)
PL (2) PL3042957T3 (es)
PT (1) PT3042957T (es)
SG (3) SG10201700096VA (es)
WO (1) WO2011009058A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2652340T3 (es) 2009-07-17 2018-02-01 Bioatla Llc Selección y evolución simultáneas e integradas de rendimiento y expresión de proteínas humanas en huéspedes de producción
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
AU2015242961B2 (en) * 2010-07-16 2017-03-02 Bioatla, Llc Novel methods of protein evolution
CA2804746C (en) 2010-07-16 2022-01-11 Jay M. Short Novel methods of protein evolution
WO2012033953A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
US20140302999A1 (en) * 2011-11-03 2014-10-09 Magdalena Leszczyniecka Method for determination of pharmacological properties of recombinant proteins
EP2991679A4 (en) * 2013-04-29 2016-12-07 Adimab Llc POLYSPECIFIC REAGENTS, PROCESS FOR THEIR PREPARATION AND USE
CA2935577C (en) * 2014-01-07 2023-04-04 Bioatla, Llc Proteins targeting orthologs
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
DK3143138T3 (da) * 2014-05-13 2022-04-25 Bioatla Inc Betinget aktive biologiske proteiner
WO2016004242A1 (en) * 2014-07-01 2016-01-07 Stc Biologics, Inc. A method for development of recombinant proteins with fingerprint like similarity to the reference product
AU2015308818B2 (en) * 2014-08-28 2021-02-25 Bioatla Llc Conditionally active chimeric antigen receptors for modified T-cells
CA2959786A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
CN107580603A (zh) 2015-02-24 2018-01-12 生物蛋白有限公司 条件活性生物蛋白
WO2017053807A2 (en) * 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
CN108473555B (zh) 2015-11-02 2022-10-25 生物蛋白有限公司 条件活性多肽
SI3455261T1 (sl) 2016-05-13 2023-01-31 Bioatla, Inc. Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
MX2020000342A (es) 2017-07-11 2020-08-17 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos.
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
MX2021005594A (es) 2018-11-13 2021-10-22 Compass Therapeutics Llc Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN111048154B (zh) * 2019-12-10 2023-06-06 上海药明生物技术有限公司 一种抗体表位作图的方法
CN111462815B (zh) * 2020-03-27 2023-05-02 上海祥耀生物科技有限责任公司 一种抗体库的构建方法及装置
US11506060B1 (en) * 2021-07-15 2022-11-22 Honeywell International Inc. Radial turbine rotor for gas turbine engine
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957858A (en) 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
AU624601B2 (en) 1988-01-21 1992-06-18 Genentech Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
EP0365627B1 (en) 1988-03-24 1993-12-22 University Of Iowa Research Foundation Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69333243T2 (de) 1992-11-24 2004-08-19 G.D. Searle & Co., Chicago Mutierte polypeptide des interleukin-3(il-3)
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US8137906B2 (en) 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
RU2363707C2 (ru) 2001-02-19 2009-08-10 Мерк Патент Гмбх Искусственные белки с пониженной иммуногенностью
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
WO2002092780A2 (en) * 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
ES2609102T3 (es) * 2003-06-27 2017-04-18 Bioren, LLC Mutagénesis por revisión
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
JP5754135B2 (ja) * 2007-03-26 2015-07-29 アジェナス インコーポレイテッド 関心対象のタンパク質の細胞表面ディスプレイ、スクリーニング、および産生
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
US9249408B2 (en) 2007-11-02 2016-02-02 The Scripps Research Institute Directed evolution using proteins comprising unnatural amino acids
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
ES2652340T3 (es) 2009-07-17 2018-02-01 Bioatla Llc Selección y evolución simultáneas e integradas de rendimiento y expresión de proteínas humanas en huéspedes de producción
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
KR20210013294A (ko) 2021-02-03
US10920216B2 (en) 2021-02-16
EP3042957A1 (en) 2016-07-13
SG10201505075TA (en) 2015-07-30
AU2010273974A8 (en) 2012-02-23
AU2015243076A1 (en) 2015-11-05
AU2019203813A1 (en) 2019-06-20
AU2015243076B2 (en) 2017-02-23
JP2017205110A (ja) 2017-11-24
US20210207129A1 (en) 2021-07-08
EP3042957B1 (en) 2017-09-13
ES2652340T3 (es) 2018-02-01
MY160472A (en) 2017-03-15
CN102625848A (zh) 2012-08-01
AU2017203243B2 (en) 2019-07-11
PL3042957T3 (pl) 2018-03-30
KR20220002712A (ko) 2022-01-06
PT3042957T (pt) 2017-12-21
BR122015012748A2 (pt) 2020-01-07
ES2581318T3 (es) 2016-09-05
AU2010273974A1 (en) 2012-02-09
MX2012000803A (es) 2012-06-01
ES2701931T3 (es) 2019-02-26
US20120245036A1 (en) 2012-09-27
SG177687A1 (en) 2012-02-28
WO2011009058A3 (en) 2011-04-14
JP2012533307A (ja) 2012-12-27
KR20120069664A (ko) 2012-06-28
DK3042957T3 (en) 2018-01-02
US10047357B2 (en) 2018-08-14
MY173037A (en) 2019-12-20
DK3406717T3 (da) 2020-03-16
DK3156485T3 (en) 2019-01-07
EP2907873B1 (en) 2016-04-06
BR112012001171B1 (pt) 2021-09-21
WO2011009058A2 (en) 2011-01-20
AU2017203243A1 (en) 2017-06-08
EP3406717B1 (en) 2019-12-11
CA2768247A1 (en) 2011-01-20
KR101823872B1 (ko) 2018-01-31
JP6193570B2 (ja) 2017-09-13
US20180371452A1 (en) 2018-12-27
EP2907873A1 (en) 2015-08-19
CA3034484A1 (en) 2011-01-20
EP3156485B1 (en) 2018-09-12
HK1210623A1 (zh) 2016-04-29
US8859467B2 (en) 2014-10-14
US20120165201A1 (en) 2012-06-28
HUE029328T2 (en) 2017-02-28
CN107090031A (zh) 2017-08-25
IN2012DN00737A (es) 2015-06-19
EP3406717A1 (en) 2018-11-28
EP2454376A4 (en) 2013-07-10
EP3636759B1 (en) 2023-10-11
KR20190017070A (ko) 2019-02-19
KR20180010347A (ko) 2018-01-30
AU2019203813B2 (en) 2021-03-11
PL2907873T3 (pl) 2016-10-31
JP6193913B2 (ja) 2017-09-06
AU2021203220A1 (en) 2021-06-10
US10106788B2 (en) 2018-10-23
EP3636759A1 (en) 2020-04-15
EP2454376A2 (en) 2012-05-23
EP3156485A1 (en) 2017-04-19
JP2015211672A (ja) 2015-11-26
SG10201700096VA (en) 2017-02-27
CA2768247C (en) 2019-04-09
EP2454376B1 (en) 2015-12-02
AU2021203220B2 (en) 2023-05-04
DK2907873T3 (en) 2016-06-13
US20150024944A1 (en) 2015-01-22
BR112012001171A2 (pt) 2017-06-13
AU2010273974B2 (en) 2016-01-14
JP6681131B2 (ja) 2020-04-15
DK3636759T3 (da) 2023-10-23

Similar Documents

Publication Publication Date Title
MX347654B (es) Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion.
TN2011000433A1 (en) Alpha -4-beta-7heterodimer specific antagonist antibody
MX353144B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
MX2009012747A (es) Produccion de proteina recombinante en celulas ebx de aves.
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
MY176026A (en) Methods and composions comprising purified recombinant polypeptides
EP2534257A4 (en) METHOD OF IDENTIFYING AND ISOLATING CELLS FOR THE EXPRESSION OF POLYPEPTIDES
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
GB201003701D0 (en) System for the expression of a protein
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
TN2014000120A1 (en) Cd27l antigen binding proteins
WO2011062997A3 (en) Human monoclonal antibodies to human nucleolin
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2008081031A3 (en) Methods of increasing the production yield of a secreted antibody in a filamentous fungus by overexpression of the chaperone bip
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
MX363690B (es) Expansión de celulas madre adultas in vitro.
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
CL2014003569A1 (es) Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter.
WO2011128820A3 (en) Methods for the analysis of breast cancer disorders
WO2011057011A3 (en) T-cell stimulating protein b and methods of use
AU2016219622A1 (en) Heterodimeric antibody FC-containing proteins and methods for production thereof
AU2011207257A8 (en) Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
UA69272U (ru) Способ выделения и очистки igm человека